MEDROXYPROGESTERONE\MEDROXYPROGESTERONE: 313 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
313
Total FAERS Reports
1 (0.3%)
Deaths Reported
15
Hospitalizations
313
As Primary/Secondary Suspect
5
Life-Threatening
13
Disabilities
Active Ingredient: MEDROXYPROGESTERONE\MEDROXYPROGESTERONE ACETATE ·
First Report: 20031220 · Latest Report: 20250726
What Are the Most Common MEDROXYPROGESTERONE\MEDROXYPROGESTERONE Side Effects?
#1 Most Reported
Drug dose omission by device
60 reports (19.2%)
#2 Most Reported
Device issue
39 reports (12.5%)
#3 Most Reported
Incorrect dose administered
26 reports (8.3%)
All MEDROXYPROGESTERONE\MEDROXYPROGESTERONE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug dose omission by device | 60 | 19.2% | 0 | 0 |
| Device issue | 39 | 12.5% | 0 | 0 |
| Incorrect dose administered | 26 | 8.3% | 0 | 0 |
| Device occlusion | 25 | 8.0% | 0 | 0 |
| Injection site indentation | 19 | 6.1% | 0 | 0 |
| Needle issue | 18 | 5.8% | 0 | 0 |
| Lipoatrophy | 16 | 5.1% | 0 | 0 |
| Product complaint | 16 | 5.1% | 0 | 0 |
| Product dose omission issue | 16 | 5.1% | 0 | 0 |
| Device leakage | 15 | 4.8% | 0 | 0 |
| Incorrect dose administered by device | 15 | 4.8% | 0 | 0 |
| Injection site pain | 15 | 4.8% | 0 | 0 |
| Injection site mass | 13 | 4.2% | 0 | 0 |
| Off label use | 13 | 4.2% | 0 | 1 |
| Device delivery system issue | 12 | 3.8% | 0 | 0 |
| Headache | 11 | 3.5% | 0 | 2 |
| No adverse event | 11 | 3.5% | 0 | 0 |
| Dizziness | 10 | 3.2% | 0 | 1 |
| Injection site bruising | 10 | 3.2% | 0 | 0 |
| Accidental exposure to product | 9 | 2.9% | 0 | 0 |
Who Reports MEDROXYPROGESTERONE\MEDROXYPROGESTERONE Side Effects? Age & Gender Data
Gender: 95.5% female, 4.5% male. Average age: 31.6 years. Most reports from: GB. View detailed demographics →
Is MEDROXYPROGESTERONE\MEDROXYPROGESTERONE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2003 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 0 |
| 2015 | 2 | 0 | 0 |
| 2016 | 6 | 0 | 0 |
| 2017 | 9 | 0 | 0 |
| 2018 | 13 | 0 | 1 |
| 2019 | 10 | 0 | 2 |
| 2020 | 37 | 0 | 0 |
| 2021 | 53 | 0 | 4 |
| 2022 | 8 | 0 | 2 |
| 2023 | 9 | 0 | 0 |
| 2024 | 11 | 0 | 1 |
| 2025 | 5 | 0 | 1 |
What Is MEDROXYPROGESTERONE\MEDROXYPROGESTERONE Used For?
| Indication | Reports |
|---|---|
| Contraception | 150 |
| Injectable contraception | 5 |
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs Alternatives: Which Is Safer?
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MEFENAMIC ACID
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MEFLOQUINE
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MEGESTROL
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MEGLUMINE
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MELATONIN
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MELOXICAM
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MELPERONE
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MELPHALAN
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MEMANTINE
MEDROXYPROGESTERONE\MEDROXYPROGESTERONE vs MENINGOCOCCAL GROUP B VACCINE
Official FDA Label for MEDROXYPROGESTERONE\MEDROXYPROGESTERONE
Official prescribing information from the FDA-approved drug label.